233 related articles for article (PubMed ID: 35060071)
21. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
22. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
Li C; Tian Y; Shen Y; Wen B; He Y
AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
[No Abstract] [Full Text] [Related]
23. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
25. Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.
Wang D; Koh ES; Descallar J; Pramana A; Vinod SK; Ho Shon I
Asia Pac J Clin Oncol; 2016 Dec; 12(4):349-358. PubMed ID: 27550522
[TBL] [Abstract][Full Text] [Related]
26. Comparison of prognostic values of primary tumor and nodal
Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978
[TBL] [Abstract][Full Text] [Related]
27. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
[TBL] [Abstract][Full Text] [Related]
29. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
Chung HW; Lee KY; Kim HJ; Kim WS; So Y
J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of metabolic tumor volume of pretreatment
Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
[TBL] [Abstract][Full Text] [Related]
31. The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.
Huang W; Liu B; Fan M; Zhou T; Fu Z; Zhang Z; Li H; Li B
Eur J Radiol; 2015 Mar; 84(3):482-488. PubMed ID: 25533718
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Metabolic Parameters of Metastatic Lymph Nodes on
Jin F; Qu B; Fu Z; Zhang Y; Han A; Kong L; Yu J
Clin Lung Cancer; 2018 Jan; 19(1):e101-e108. PubMed ID: 28690012
[TBL] [Abstract][Full Text] [Related]
34. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.
Lee P; Bazan JG; Lavori PW; Weerasuriya DK; Quon A; Le QT; Wakelee HA; Graves EE; Loo BW
Clin Lung Cancer; 2012 Jan; 13(1):52-58. PubMed ID: 21703935
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.
Im HJ; Pak K; Cheon GJ; Kang KW; Kim SJ; Kim IJ; Chung JK; Kim EE; Lee DS
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):241-51. PubMed ID: 25193652
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
37. A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [
Zhang L; Xu C; Zhang X; Wang J; Jiang H; Chen J; Zhang H
Eur Radiol; 2023 Mar; 33(3):1757-1768. PubMed ID: 36222865
[TBL] [Abstract][Full Text] [Related]
38. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer.
Kong FS; Li L; Wang W; Campbell J; Waller JL; Piert M; Gross M; Cheng M; Owen D; Stenmark M; Huang KC; Frey KA; Ten Haken RK; Lawrence TS
Radiother Oncol; 2019 Mar; 132():241-249. PubMed ID: 30389239
[TBL] [Abstract][Full Text] [Related]
39. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P
Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity in tumours: Validating the use of radiomic features on
Krarup MMK; Nygård L; Vogelius IR; Andersen FL; Cook G; Goh V; Fischer BM
Radiother Oncol; 2020 Mar; 144():72-78. PubMed ID: 31733491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
